



# Market Announcement

11 April 2019

---

## Paradigm Biopharmaceuticals Limited (ASX: PAR) – Trading Halt

### Description

The securities of Paradigm Biopharmaceuticals Limited ('PAR') will be placed in trading halt at the request of PAR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 15 April 2019 or when the announcement is released to the market.

### Issued by

#### **Cheng Tang**

Senior Adviser, Listings Compliance (Melbourne)



11 April 2019

**By email: [kate.kidson@asx.com.au](mailto:kate.kidson@asx.com.au)**

Kate Kidson  
Adviser, Listings Compliance (Melbourne)  
ASX Limited

Dear Kate

### **Request for a trading halt**

Paradigm Biopharmaceuticals Limited ACN 169 346 963 (ASX: PAR) (the **Company**), requests an immediate trading halt be granted for all of its securities.

In accordance with Listing Rule 17.1, the Company advises:

- the trading halt is requested pending an announcement regarding the Company's Phase 2b randomised, double-blind, placebo controlled OA/BMEL clinical trial secondary endpoints/results;
- the trading halt is requested to apply until the earlier of an announcement by the Company on the results of the clinical trial, or the commencement of normal trading on Monday 15 April 2019; and
- the Company is not aware of any reason why a trading halt should not be granted.

Please contact us should you have any questions.

Yours faithfully

Kevin Hollingsworth  
Company Secretary

For and on behalf of the Board of Paradigm Biopharmaceuticals Limited

Paradigm BioPharmaceuticals Ltd  
C/- Hollingsworth & Co Pty Ltd, Level 2, 517 Flinders Lane, Melbourne, VIC, 3000, AUSTRALIA  
ABN: 94 169 346 963  
Web: <http://paradigmbiopharma.com/>